node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
AADAT | AFMID | A0A2U3ZJ32 | A0A2U3ZWX5 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | 0.953 |
AADAT | CCBL1 | A0A2U3ZJ32 | A0A2U3VDN6 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Kynurenine--oxoglutarate transaminase 1. | 0.937 |
AADAT | CCBL2 | A0A2U3ZJ32 | A0A2U3WJI4 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Kynurenine--oxoglutarate transaminase 3. | 0.945 |
AADAT | KMO | A0A2U3ZJ32 | A0A2U3WXW2 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Kynurenine 3-monooxygenase; Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. | 0.954 |
AADAT | KYNU | A0A2U3ZJ32 | A0A2U3WBM3 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Kynureninase; Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3- hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3- hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity. Belongs to the kynureninase family. | 0.940 |
AADAT | TDO2 | A0A2U3ZJ32 | A0A2U3VHK8 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | Tryptophan 2,3-dioxygenase; Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L- tryptophan to N-formyl-L-kynurenine. Catalyzes the oxidative cleavage of the indole moiety. | 0.433 |
AFMID | AADAT | A0A2U3ZWX5 | A0A2U3ZJ32 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | 0.953 |
AFMID | CCBL1 | A0A2U3ZWX5 | A0A2U3VDN6 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Kynurenine--oxoglutarate transaminase 1. | 0.971 |
AFMID | CCBL2 | A0A2U3ZWX5 | A0A2U3WJI4 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Kynurenine--oxoglutarate transaminase 3. | 0.974 |
AFMID | DDC | A0A2U3ZWX5 | A0A2U3WZH7 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | aromatic-L-amino-acid decarboxylase. | 0.927 |
AFMID | IDO1 | A0A2U3ZWX5 | A0A2U3VI51 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Indoleamine 2,3-dioxygenase 1. | 0.951 |
AFMID | IDO2 | A0A2U3ZWX5 | A0A2U3VI31 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Indoleamine 2,3-dioxygenase 2. | 0.975 |
AFMID | KMO | A0A2U3ZWX5 | A0A2U3WXW2 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Kynurenine 3-monooxygenase; Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. | 0.971 |
AFMID | KYNU | A0A2U3ZWX5 | A0A2U3WBM3 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Kynureninase; Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3- hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3- hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity. Belongs to the kynureninase family. | 0.977 |
AFMID | PCK2 | A0A2U3ZWX5 | A0A2U3ZHI8 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Phosphoenolpyruvate carboxykinase [GTP], mitochondrial isoform X1. | 0.814 |
AFMID | TDO2 | A0A2U3ZWX5 | A0A2U3VHK8 | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | Tryptophan 2,3-dioxygenase; Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L- tryptophan to N-formyl-L-kynurenine. Catalyzes the oxidative cleavage of the indole moiety. | 0.976 |
CCBL1 | AADAT | A0A2U3VDN6 | A0A2U3ZJ32 | Kynurenine--oxoglutarate transaminase 1. | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial isoform X1. | 0.937 |
CCBL1 | AFMID | A0A2U3VDN6 | A0A2U3ZWX5 | Kynurenine--oxoglutarate transaminase 1. | Kynurenine formamidase; Catalyzes the hydrolysis of N-formyl-L-kynurenine to L- kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. | 0.971 |
CCBL1 | CCBL2 | A0A2U3VDN6 | A0A2U3WJI4 | Kynurenine--oxoglutarate transaminase 1. | Kynurenine--oxoglutarate transaminase 3. | 0.902 |
CCBL1 | KMO | A0A2U3VDN6 | A0A2U3WXW2 | Kynurenine--oxoglutarate transaminase 1. | Kynurenine 3-monooxygenase; Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. | 0.965 |